📄 Direct examination of Roger Martz (part 2) — Tuesday, July 25, 1995
Address:
C:\DEPT103\CRIMINAL\1995\JUL\25\DIRECT-EXAMINATION-OF-ROGER-MA.DOC
TRIAL
▲ Day 121 of 167

Direct examination of Roger Martz (part 2)

Witness: Roger Martz
Examiner: Robert Blasier
Called by: Defense • Date: Tuesday, July 25, 1995 • Utterances: 650
Defense attorney Robert Blasier continues cross-examining FBI forensic chemist Roger Martz about his EDTA testing of blood found on OJ Simpson's sock and the back gate at Nicole Brown Simpson's condo. Blasier systematically dismantles Martz's methodology — showing he had no prior EDTA testing experience, used chromatography poorly suited to the task, chose the least sensitive method to look for the confirming 132 daughter ion, and never attempted to quantify EDTA levels. Critically, Martz concedes that both the sock and gate blood results are 'consistent with the presence of EDTA,' while a prosecution letter requesting the tests used language suggesting a desired outcome.
1 (The following proceedings were held in open court:)
2 THE COURT:

All right. Thank you, counsel. Proceed.

3 MR. BLASIER:

Mr. Martz, have you had a chance to read that paragraph?

4 MR. MARTZ:

Yes, I did.

5 MR. BLASIER:

Is that the paragraph that tells you what they wanted you to do?

6 MR. MARTZ:

Yes.

7 MR. BLASIER:

What does that tell you to do?

8 MR. MARTZ:

Do you want me to read it?

9 MR. BLASIER:

Can I put it on the elmo?

10 THE COURT:

Put on both pages.

11 MR. BLASIER:

Both pages.

12 (Discussion held off the record between Defense counsel.)
13 MR. BLASIER:

Your Honor, I was only going to refer to the last page.

14 MS. CLARK:

Objection under 356, your Honor.

15 THE COURT:

Well, then you can go into that under cross-examination, counsel.

16 (Brief pause.)
17 THE COURT:

Back it out just a little, Mr. Harris.

18 (Brief pause.)
19 THE COURT:

Thank you.

20 MR. BLASIER:

Agent Martz, could you read that from there?

21 MR. MARTZ:

"We would like you to test these items for the presence/absence of EDTA in order to refute the possibility that the stains on the sock, item 13, could have come from Nicole's reference sample, 59 or 72. Similarly, we would like you to test item 117 to refute the possibility that it could have come from Simpson's reference sample, no. 17."

KEY QUOTE
22 MR. BLASIER:

Now, actually I'm going to show the first page.

23 (Brief pause.)
24 MR. BLASIER:

Did you interpret by the way that request was made as a request to do some testing and they wanted a particular result?

25 MR. MARTZ:

I didn't--I didn't infer that, no.

26 MR. BLASIER:

Did you, when you approached the testing that you did, did you do it with an idea that you were trying to get one result as opposed to another result?

27 MR. MARTZ:

No.

28 MR. BLASIER:

Now, let me show you the first page of that letter and could you read just the first sentence.

29 MR. MARTZ:

"This letter is to describe the items we are sending to you in order to detect the presence or absence of EDTA in specific bloodstains which are of significance in this case."

30 MR. BLASIER:

Now, were you ever requested by the Prosecution by way of this letter to try and quantify the amount of EDTA should you find it?

31 MR. MARTZ:

I didn't interpret it that way.

32 MR. BLASIER:

Mr. Martz, up to the time that you were contacted by the Prosecutors in this case, have you ever worked in any manner or fashion with EDTA?

33 MR. MARTZ:

I have certainly worked with it, but I have never tried to analyze for it.

34 MR. BLASIER:

Had you ever been asked to determine whether it was present in blood or any other substance?

35 MR. MARTZ:

No.

36 MR. BLASIER:

Had you ever been--ever attempted to design a test to extract EDTA from dried bloodstains?

37 MR. MARTZ:

No.

38 MR. BLASIER:

Now, is the technique that you used that we have been talking about yesterday, the--I want you to tell us what that technique is called.

39 MR. MARTZ:

Well, the technique that I primarily use was electrospray tandem mass spectrometry.

40 MR. BLASIER:

You used chromatograph as well, did you?

41 MR. MARTZ:

Yes.

42 MR. BLASIER:

What form of chromatography did you use?

43 MR. MARTZ:

I used liquid chromatography.

44 MR. BLASIER:

Are there other forms of chromatography?

45 MR. MARTZ:

The more conventional chromatography with mass spectrometry would be gas chromatography.

46 MR. BLASIER:

Now, did you hear yesterday Miss Clark asking some questions about the effect or the relationship between electrospray and chromatography?

47 MR. MARTZ:

Yes.

48 MR. BLASIER:

Is it accurate that electrospray has nothing to do with chromatography?

49 MR. MARTZ:

Well, conventionally you use chromatography with electrospray.

50 MR. BLASIER:

But does chromatography--I'm sorry. Is electrospray involved in the chromatography stage at all?

51 MR. MARTZ:

Well, it is a precursor to chromatography.

52 MR. BLASIER:

A precursor?

53 MR. MARTZ:

Right. That is the way that we do electrospray at the FBI laboratory with liquid chromatography.

54 MR. BLASIER:

That you do the electrospray before you do the chromatography?

55 MR. MARTZ:

No, the chromatography precedes the electrospray. They work in conjunction. You need--in order to do electrospray you need a liquid, so to get the liquid you use liquid chromatography.

56 MR. BLASIER:

But the method of chromatography--the electrospray happens after the chromatography is done; isn't that right?

57 MR. MARTZ:

That's correct.

58 MR. BLASIER:

Now, you use liquid chromatography--you indicated that gas chromatography is a more commonly used procedure?

59 MR. MARTZ:

That's correct.

60 MR. BLASIER:

And could you have done gas chromatography in this case?

61 MR. MARTZ:

Not without manipulating the chemical EDTA. EDTA will not gas--work on the gas chromatography.

62 MR. BLASIER:

Do you know what the technique derivatizing samples is?

63 MR. MARTZ:

Yes.

64 MR. BLASIER:

Is that the technique that you would use if you wanted to use gas chromatography?

65 MR. MARTZ:

It is a technique that could be used. I have not tried it with EDTA. I don't know how successful it is.

66 MR. BLASIER:

And would you agree that that form of chromatography is much better than the form that you used?

67 MR. MARTZ:

No, I would not agree with that.

68 MR. BLASIER:

Now, are you familiar with the method of liquid chromatography called gradient elution?

69 MR. MARTZ:

It sounds something familiar.

70 MR. BLASIER:

All right. Have you ever used that?

71 MR. MARTZ:

Not per se.

72 MR. BLASIER:

Now, do you know whether that is a better chromatography procedure for what you were trying to do than what you did?

73 MR. MARTZ:

I wouldn't say that it was or wasn't, no.

74 MR. BLASIER:

Now, did--were you listening yesterday when there were questions being asked about the efficiency, if you will, of your chromatography method that you used?

75 MR. MARTZ:

Right.

76 MR. BLASIER:

And could you tell us whether your method does not effectively separate compounds by retention time?

77 MR. MARTZ:

It does not. It--the way that I used it, it is not very effective in separating compounds. I can give you an analogy. If everyone in here was to run a marathon, people would finish at different times. Very few people would finish at two hours. Some people may take six hours. Well, with the type of chromatography that I used it would be more like a 50-yard dash. We would all run a 50-yard dash. We would all finish about the same time.

78 THE COURT:

Agent, the world's best is 2:06.

KEY QUOTE
79 MR. BLASIER:

You are familiar with other methods of chromatography that work better than the one you used, aren't you?

80 MS. CLARK:

Objection. That is vague. For what?

81 THE COURT:

Overruled.

82 MR. MARTZ:

My purpose in chromatography was not for identification. I did not even consider that in the identification of these compounds.

83 MR. BLASIER:

Your Honor, I move to strike that answer as nonresponsive.

84 THE COURT:

Overruled.

85 MR. BLASIER:

Agent Martz, are you familiar with other techniques of chromatography that would provide better information in terms of separating compounds than the one you used?

86 MR. MARTZ:

Yes, and I did use a better one on the 28th which gave separation for EDTA.

87 MR. BLASIER:

All right. The 28th of February?

88 MR. MARTZ:

Yes, that's correct.

89 MR. BLASIER:

What was the difference in the method that you used from the 22nd to the 28th?

90 MR. MARTZ:

The one did not involve mass spectrometry. I was able to use a compound which is not very friendly to the electrospray.

91 MR. BLASIER:

Now, so the first step that you tried on February--February 22nd is where you tested for the first time under the method that we have been talking about, the sock and the gate stains; is that correct?

92 MR. MARTZ:

Well, not necessarily. I mean, the 19th I did a method of electrospray mass spectrometry.

93 MR. BLASIER:

I'm sorry, go ahead.

94 MR. MARTZ:

That test we have failed to mention so far.

95 MR. BLASIER:

Let's mention it. What method was that?

96 MR. MARTZ:

It was the same thing. It was electrospray mass spectrometry using LC.

97 MR. BLASIER:

That is using what is called the negative ion mode; is that correct?

98 MR. MARTZ:

That is correct, which is more selective than the positive ion mode.

99 MR. BLASIER:

Did you find that that was much less sensitive than the positive ion mode?

100 MR. MARTZ:

It was less sensitive.

101 MR. BLASIER:

About how many orders of magnitude?

102 MR. MARTZ:

It was approximately ten, ten times less sensitive.

103 MR. BLASIER:

All right. So it was after you used that method that it was ten times less sensitive that you used the positive ion mode that we have been talking about that is more sensitive, correct?

104 MR. MARTZ:

In this particular case it ended up being more sensitive, yes.

105 MR. BLASIER:

You knew at the time that you did the negative ion mode, once you saw the results, that it was not a particularly sensitive test; is that correct?

106 MR. MARTZ:

It certainly--I would agree with that. It was not that sensitive of a test.

107 MR. BLASIER:

So is it fair to say that you decided that you needed to do something a little bit more sensitive?

108 MR. MARTZ:

No, that is not fair to say at all.

109 MR. BLASIER:

Okay. But you did?

110 MR. MARTZ:

I did, yes.

111 MR. BLASIER:

Now, if the method that you chose for the liquid chromatography was not particularly good, what was the purpose of doing it?

112 MR. MARTZ:

Well, I have a very expensive instrumentation that has unique capabilities. One of those is to separate out by masses. This is a tandem mass spectrometer. I can get much better separation using the mass spectrometer than I can the chromatography and I elected to use the chromatography for the introduction of the sample to the mass spectrometer or the first quadrupole.

113 MR. BLASIER:

You introduce sample directly into the mass spec?

114 MR. MARTZ:

Yes, you can.

115 MR. BLASIER:

Let me ask you again, was there a reason why you used the chromatography stage if you didn't really need to and it wasn't a particularly good method?

116 MR. MARTZ:

I didn't say I didn't need to in this particular case. With EDTA it is needed for it to ionize, otherwise it would have to be derivatized. Using--you cannot do direct injection of EDTA through solid probe or you cannot do it through GC/MS. The technique that I had available was the LC/ms using electrospray.

117 MR. BLASIER:

How much time did you spend designing the method that you were going to use in this case?

118 MR. MARTZ:

Umm, that is difficult to determine. I mean, it includes twenty years' experience that I have with mass spectrometry, knowing all the things about the instruments, what is available, what will work, what won't work, it would be very difficult to put a time on how long it took to develop this procedure, because it encompasses twenty years' of experience or eighteen years' of experience with the instrumental technique. The actual hours performing the EDTA analysis was probably in the order of maybe a week would be a good estimation.

119 MR. BLASIER:

And you had never done this kind of work before with EDTA, had you?

120 MR. MARTZ:

No, I have never analyzed for EDTA in the past.

121 MR. BLASIER:

And when you were requested to do this testing for the District Attorney, did you--was it your understanding that you had to develop a method that would work?

122 MR. MARTZ:

Well, I wouldn't necessarily develop a method. The method is already developed for the identification using electrospray. All I had to do was identify a different chemical. There is no really method development.

123 MR. BLASIER:

So you spent a week doing that?

124 MR. MARTZ:

In order to get a procedure that was--was sensitive enough, in order to distinguish between a blood that was preserved with EDTA and blood that wasn't.

125 (Discussion held off the record between Defense counsel.)
126 MR. BLASIER:

By the way, is the method that you used--any of the methods that you used quantitative methods?

127 MR. MARTZ:

I did not specifically use these methods to quantitate the amount of EDTA.

128 MR. BLASIER:

So the purpose of the test, the way you at the time set it up, is it fair to say that what you were trying to do is just determine is EDTA there or isn't it?

129 MR. MARTZ:

No. I was trying to determine whether or not the stain came from EDTA-preserved blood.

KEY QUOTE
130 MR. BLASIER:

And the method you chose was a method that would identify it but not quantify it? Is that accurate?

131 MR. MARTZ:

That would easily distinguish between whether or not it was preserved or non-preserved.

132 MR. BLASIER:

Was your method designed to determine whether it was there or not, as opposed to telling you how much was there?

133 MR. MARTZ:

No. My method was designed to determine whether or not it was preserved blood with EDTA.

134 (Discussion held off the record between Deputy District Attorney and Defense counsel.)
135 MR. BLASIER:

Agent Martz, let me show you first chromatograms 1262-A and 1262-B. And do you recognize those?

136 MR. MARTZ:

Yes, I do.

137 MR. BLASIER:

What are they?

138 MR. MARTZ:

These were 50 part per million standards that I had run of EDTA on--I don't see the date here, but was this on the 22nd?

139 MR. BLASIER:

Let me check.

140 (Brief pause.)
141 MR. BLASIER:

I believe that was the 22nd.

142 MR. MARTZ:

Okay.

143 MR. BLASIER:

Your Honor, could we have slide 1257-T, please, or I'm sorry, V.

144 (Brief pause.)
145 MR. BLASIER:

Now, Mr. Martz, would you look at the chart, please, and tell me if that accurately charts the ion count that you got for 50 parts per million on two separate runs on February 22nd?

146 MR. MARTZ:

Umm, no, I don't think--I don't believe that it does.

147 MR. BLASIER:

What is inaccurate about it?

148 MR. MARTZ:

Well, I think a more accurate representation of ion count is the area and not the peak height.

149 MR. BLASIER:

Does your electrospray method result in ionization that widely or fluctuates from a large extent from one test to the next?

150 MR. MARTZ:

I think it would depend on which--what adjective did you use?

151 MR. BLASIER:

I said "Wildly," but I will say to large extremes?

152 MR. MARTZ:

It would depend on your definition of "Large extremes." It will fluctuate.

153 MR. BLASIER:

So as I understand your testimony, you think that my chart is misleading because I have it based on ion counts?

154 MR. MARTZ:

Well, you have it based on the peak height and not the peak area.

155 MR. BLASIER:

Okay.

156 MR. MARTZ:

The area would be a better depiction of the ion count.

157 MR. BLASIER:

Okay. Is it misleading that way?

158 MR. MARTZ:

Well, it depends on what you are trying to prove. If you want to say that the instrument fluctuates, you wouldn't use the peak height, you would use the peak area because it is a better representation of the total ion count.

159 MR. BLASIER:

But looking at the peak height also demonstrates that it fluctuates quite a bit, doesn't it?

160 MR. MARTZ:

It fluctuates quite a bit in peak height, yes.

161 MR. BLASIER:

And would it be unusual, as we have here, as we have a seven-fold difference looking at the same thing, the same day?

162 MR. MARTZ:

It depends. From injection to an injection it would be somewhat unusual, but at the beginning of the day versus the end of the day it may not be that unexpected. And again, if you really want a true depiction of the good fluctuation, you would want to look at the peak area; not the peak heights. And the areas--

163 MR. BLASIER:

Does the peak height in your opinion bear any relationship to the quantity of EDTA that you are looking at?

164 MR. MARTZ:

Not a very good one.

165 MR. BLASIER:

Okay. Let me show you People's no. 541. Have you seen that chart before?

166 MR. MARTZ:

Yes, I have.

167 MR. BLASIER:

Did you make it?

168 MR. MARTZ:

Yes, I did.

169 MR. BLASIER:

Can we put this on the elmo, please?

170 (Brief pause.)
171 MR. BLASIER:

Now, Agent Martz, this is a chart that you prepared, correct?

172 MR. MARTZ:

That's correct.

173 MR. BLASIER:

It is a chart based on ion count, isn't it?

174 MR. MARTZ:

It is based on the peak area, as I mentioned, that you should have done.

175 MR. BLASIER:

Look on the left side of that. Can you see what the scale says?

176 MR. MARTZ:

Right.

177 MR. BLASIER:

What does it say?

178 MR. MARTZ:

Ion count. It is in peak area, which is the better way to depict the ion count.

179 MR. BLASIER:

Why is the labeled "Ion count" if it is peak area?

180 MR. MARTZ:

It is the ion count of the peak, the whole peak.

181 MR. BLASIER:

Okay. Do you agree that if you look at area or ion peak your method of electrospray causes--you would expect that it would cause substantial variation from one test to the next or could?

182 (No audible response.)
183 MR. BLASIER:

That is not unusual, is it?

184 MR. MARTZ:

It can happen.

185 MR. BLASIER:

Your Honor, may I have a minute?

186 THE COURT:

Certainly.

187 (Discussion held off the record between Defense counsel.)
188 MR. BLASIER:

Let me show you Defense 1259-B and 1259-A. And ask if you recognize those?

189 MR. MARTZ:

Yes. Those are runs that I had done on my question 206.

190 MR. BLASIER:

And Q206 was what?

191 MR. MARTZ:

I believe that was the sock.

192 MR. BLASIER:

Could we have slide 1257-P, please.

193 (Brief pause.)
194 MR. BLASIER:

Agent Martz, would you look at the monitor and tell us if that appears to be not to scale, but an accurate depiction of where you got Q206 from?

195 MR. MARTZ:

That's correct.

196 MR. BLASIER:

And you actually had the sock itself?

197 MR. MARTZ:

Yes, I did.

198 MR. BLASIER:

And when you got the sock was the green area indicated on the chart already cut out?

199 MR. MARTZ:

Yes, it was.

200 MR. BLASIER:

And you then took a cutting from the edge area of the stain?

201 MR. MARTZ:

That's correct.

202 MR. BLASIER:

Now, you were also sent A--another swatch inside a little aliquot tube, were you not?

203 MR. MARTZ:

That's correct.

204 MR. BLASIER:

That is what you call Q207?

205 MR. MARTZ:

Yes.

206 MR. BLASIER:

You never ran a test on that in the positive ion mode, the mode that we have been talking about, for Q207, did you?

207 MR. MARTZ:

I don't believe I did. I only ran that on the first day.

208 MR. BLASIER:

And Q207, so--is it pair to say you made no estimate on Q207 as to how much blood might be on that?

209 MR. MARTZ:

Umm, by looking at it, it appeared that it was covered with blood, but how much, other than it was covered, I don't know.

210 MR. BLASIER:

Now, why didn't you test Q207, which was from the large stain, in the positive ion mode?

211 MR. MARTZ:

Because I had tested it on the negative ion mode.

212 MR. BLASIER:

You remember when we talked in Washington about a week and a half ago?

213 MR. MARTZ:

Yeah.

214 MR. BLASIER:

And do you recall my requesting you about Q207 about why you didn't test it?

215 MR. MARTZ:

I can't remember, to be perfectly honest with you.

216 MR. BLASIER:

Do you remember telling me that you didn't know what Q207 was?

217 MR. MARTZ:

I did mention I didn't know what Q207 was at the time, yes.

218 MR. BLASIER:

Okay.

219 (Discussion held off the record between Defense counsel.)
220 MR. BLASIER:

Your Honor, may I have a photograph marked?

221 THE COURT:

Yes. 1263.

222 MR. BLASIER:

1263.

223 (Deft's 1263 for id = letter)
224 MR. BLASIER:

Mr. Martz, could you take a look at 1263 and tell me if that is a picture of Q207?

225 MR. MARTZ:

Yes, that's correct.

226 MR. BLASIER:

Your Honor, I think that last document was 1263, a two-page letter.

227 THE COURT:

Was never marked.

228 MR. BLASIER:

No, it was marked, because I wrote it down.

229 THE COURT:

It wasn't marked on the record, counsel.

230 (Brief pause.)
231 THE COURT:

All right. 1263 will be the letter and 1264 will be a photograph of Q207. 1263, what is the date on the letter, counsel?

232 MR. SCHECK:

February 16, 1995.

233 THE COURT:

Thank you.

234 (Deft's 1264 for id = photograph)
235 MR. BLASIER:

I would like to put Q207 on the elmo.

236 (Brief pause.)
237 MR. BLASIER:

Agent Martz, that is a picture of what was sent to you, Q207?

238 MR. MARTZ:

That's correct.

239 MR. BLASIER:

And you now know that that came from the stain area that had been cut out of the sock?

240 MR. MARTZ:

Yes.

241 MR. BLASIER:

Once you found out what that was, did you ever request to have it sent back so that you could run tests, positive ion tests on that?

242 MR. MARTZ:

No.

243 (Discussion held off the record between Defense counsel.)
244 MR. BLASIER:

Could we have 1257-R.

245 (Discussion held off the record between Defense counsel.)
246 MR. BLASIER:

Agent Martz, is the chart that is now on the screen an accurate depiction of the two tests that you ran on Q206, the stain from the--the cutting from the edge of the stain?

247 MR. MARTZ:

Two of the tests that I ran, yes.

248 MR. BLASIER:

And do you agree that the peaks demonstrated on the chart were peaks that you found in your testing?

249 MR. MARTZ:

Yes, that's correct.

250 MR. BLASIER:

Now, would you agree that you detected the presence of the 293 parent ion which is the parent ion for EDTA?

251 MR. MARTZ:

Umm, I detected the 160 ion which came from the parent ion of 293.

252 MR. BLASIER:

Well, isn't it true that the machine is set so that it only let's through the 293 parent ion?

253 MR. MARTZ:

That's correct.

254 MR. BLASIER:

So is it accurate to say that you can conclude from that chart that you have found both the 293 parent ion and the 160 daughter ion?

255 MR. MARTZ:

That's correct.

256 MR. BLASIER:

All right. Now, Agent Martz, would you agree that the pattern that you got on the sock, Q206, is consistent with the presence of EDTA?

257 MR. MARTZ:

Umm, it certainly warrants further testing. It responded like EDTA responded, yes.

258 MR. BLASIER:

Is it consistent with the presence of EDTA?

259 MR. MARTZ:

Yes.

260 (Discussion held off the record between Defense counsel.)
261 MR. BLASIER:

Let me show you 1259-C.

262 (Discussion held off the record between Deputy District Attorney and Defense counsel.)
263 MR. BLASIER:

And could you tell was that is, please?

264 MR. MARTZ:

That is A--the daughter ion spectrum or chromatogram that I had run for Q206.

265 MR. BLASIER:

And let's put that on the elmo.

266 MR. BLASIER:

When you run the full daughter, what is it that you are looking for?

267 MR. MARTZ:

Well, in this particular case I'm looking for the 160 to be the base peak, the 293 to be the second largest peak and the 132 ion to be about a third the size of the parent ion, so I'm looking for three ions in certain ratios.

268 MR. BLASIER:

Okay. And one of those is the 132, correct?

269 MR. MARTZ:

That's correct.

270 MR. BLASIER:

Now, you have already detected the 160 in the parent ion and in this sample, have you not?

271 MR. MARTZ:

Yes, I have.

272 MR. BLASIER:

Now, what is the range that you scan in looking for the 132 daughter ion with this chart?

273 MR. MARTZ:

In this particular experiment I set up scanning mass 130 to mass 295.

274 MR. BLASIER:

Now, did you--were you following the analogy that we were talking about yesterday of a TV camera panning back and forth?

275 MR. MARTZ:

Do I understand that analogy?

276 MR. BLASIER:

Yes.

277 MR. MARTZ:

Yes.

278 MR. BLASIER:

Is that a fair analogy?

279 MR. MARTZ:

Sure, yes.

280 MR. BLASIER:

And would you agree that if you scan from 130 to--what did you say?

281 MR. MARTZ:

295.

282 MR. BLASIER:

--to 295, you are looking for a lot of things other than 132?

283 MR. MARTZ:

That's correct.

284 MR. BLASIER:

And would you agree also that under that particular method it is--if 132 is there you are not going to be looking at it very much at all?

285 MR. MARTZ:

Well, it is relative. I mean, every 1.5 seconds I am looking at it for a considerable amount of time. It is all relative.

286 MR. BLASIER:

Do you know what selected reaction monitoring is?

287 MR. MARTZ:

Yes, I do.

288 MR. BLASIER:

What is that?

289 MR. MARTZ:

That is where you look for one ion coming from another ion.

290 MR. BLASIER:

And is that more sensitive than the technique you used?

291 MR. MARTZ:

It was similar to the first technique that I had used. It is certainly more sensitive than this technique that I use for the confirmation.

292 MR. BLASIER:

Now, when you were looking for the 160 daughter ion, the scans that you did were generally from what range to what range?

293 MR. MARTZ:

I generally scan on two masses to either side; 158 to 162.

294 MR. BLASIER:

Now, is it your experience that your machine drifts that much so that you need to have that wide a range?

295 MR. MARTZ:

Oh, no. No, no. That is not the purpose for that at all.

296 MR. BLASIER:

Okay.

297 MR. MARTZ:

Every now and then you will have what is called a dynamic mass spectrum where everything comes out and you will get every ion, so to avoid the possibility of a misinterpretation I scan on either side to ensure that the mass that comes out is the mass that I'm looking for. In other words, if mass 160 came out along with every other mass I wouldn't be able to distinguish that was the 160 only. I'm very interested in detecting 160 and no other ions, so I always scan on either side to ensure that a mistake is not made.

298 MR. BLASIER:

And would you agree that you wind up with lower peaks than if you were scanning just at 160 and it happened to be at 160 where it is supposed to be?

299 MR. MARTZ:

Yes.

300 MR. BLASIER:

So that particular method that you used, you sacrifice peak height for a little bit more range that you look at to make sure that you are not making a mistake?

301 MR. MARTZ:

Well, for specificity you want to be correct.

302 MR. BLASIER:

Okay. And now, selected reaction monitoring is where you just look at 160, right?

303 MR. MARTZ:

Right.

304 MR. BLASIER:

Now, of those three methods, the full daughter that we had on the chart, scanning a range two to either side of 132, or selected reaction monitoring, that is looking just at 132, which is the least likely to find 132?

305 MR. MARTZ:

The full scan.

306 MR. BLASIER:

Now, when you decided that you wanted to determine whether the 132 was present in what you found from the blood on the back--on the sock, why did you pick the method that was the least likely to find it?

307 MR. MARTZ:

Because it is the most or the best way to positively identify a chemical. You've got to remember here you don't want to misidentify a chemical. If I identify something, I want to identify it to the exclusion of all other chemicals, and for me to do that I have to do this experiment.

308 MR. BLASIER:

Were you interested in finding out whether the 132 was present?

309 MR. MARTZ:

Of course I was.

310 MR. BLASIER:

And of the three methods we described, you used the one that was least likely to find this, correct?

311 MR. MARTZ:

I don't know that I agree with that. I mean, my purpose was to identify a chemical and this is the only means that I had to identify that chemical, and that is why I selected that particular--it had nothing to do with sensitivity. This is what I need to do to identify a chemical.

312 MR. BLASIER:

When you say that is the only means you had to identify the 132 ion--

313 MR. MARTZ:

To identify EDTA.

314 MR. BLASIER:

Okay. Was that the only method you had to identify the 132 method that you knew would be there if it was EDTA?

315 MS. CLARK:

Objection. That is argumentative and also calls for speculation, assumes facts not in evidence.

316 THE COURT:

Overruled.

317 MR. MARTZ:

Could you repeat that question?

318 MR. BLASIER:

I'm not sure I can.

319 THE COURT:

Was this the only method that you had to identify the 132 ion that you knew would be there.

320 MR. BLASIER:

That was it?

321 MR. MARTZ:

There is many methods to identify a 132 ion. This is not the only way to identify a 132 ion, I would agree with that.

322 MR. BLASIER:

Did you ever run a scan that looked at two sides from 130 to 134 to try and find the 132 daughter ion?

323 MR. MARTZ:

No.

324 MR. BLASIER:

Did you ever use selected reaction monitoring to look just at the 132 to see how much might be there?

325 MR. MARTZ:

No.

326 MR. BLASIER:

Let me show you 1260-A and 1260-B. I show you 1260-A and 1260-B and ask you to tell us what those are.

327 MR. MARTZ:

Those were analysis that I had done from the stain from the gate, my Q204.

328 MR. BLASIER:

And using the positive ion mode that we have been talking about, you looked for that twice?

329 MR. MARTZ:

That's correct.

330 MR. BLASIER:

Hold on to that. Now, it is your understanding that this stain came from a bloodstain found on the back gate in Nicole brown Simpson's condominium?

331 MR. MARTZ:

That's correct.

332 MR. BLASIER:

Numbered 117?

333 MR. MARTZ:

Yes.

334 MR. BLASIER:

May we have 1257-T.

335 (Brief pause.)
336 MR. BLASIER:

Agent Martz, would you agree that the chart on the screen accurately portrays the two tests, the two positive ion tests that you did of the stain, the blood from the stain from the back gate?

337 MR. MARTZ:

Yes.

338 MR. BLASIER:

And would you agree that you identified peaks in those two charts?

339 MR. MARTZ:

I don't know if the word is "Identify peaks." I found two peaks.

340 MR. BLASIER:

You found?

341 MR. MARTZ:

Yeah.

342 MR. BLASIER:

Okay. And by the way, the retention time on these two charts and the retention time on the sock charts, are they consistent also with EDTA?

343 MR. MARTZ:

Yes.

344 MR. BLASIER:

Now, would you agree that the two charts that are up on the screen from the gate demonstrate the presence of the 293 parent ion and the 160 daughter ion?

345 MR. MARTZ:

Yes.

346 MR. BLASIER:

Would you agree that those charts--that what you found in those charts is consistent with the presence of EDTA?

347 MR. MARTZ:

Umm, yes.

348 MR. BLASIER:

Did you ever in these two samples look for the 132 daughter ion using a scan of 130 to 134?

349 MR. MARTZ:

No.

350 MR. BLASIER:

Did you ever, with these two samples, look for the daughter ion by doing selected reaction monitoring, that is, looking just at 132?

351 MR. MARTZ:

No.

352 (Discussion held off the record between Defense counsel.)
353 MR. BLASIER:

Now, could we go back to the elmo and I would like to mark another picture.

354 THE COURT:

1265.

355 (Deft's 1265 for id = photograph)
356 THE COURT:

This is a photo of what, Mr. Blasier?

357 MR. BLASIER:

It is a photo of the sock.

358 THE COURT:

Thank you.

359 MR. BLASIER:

Agent Martz, let me show you what has been marked 1265, Defense exhibit, and could you tell was that is?

360 MR. MARTZ:

That is a picture that I took of the sock when I received it in the laboratory.

361 MR. BLASIER:

Could we put this on the elmo, please?

362 THE COURT:

Yes.

363 (Brief pause.)
364 MR. BLASIER:

Can you zoom in a little more on that.

365 (Brief pause.)
366 MR. BLASIER:

Now, Agent Martz, can you look at your monitor. Is that an accurate picture of the sock after you did your cutting?

367 MR. MARTZ:

Yes.

368 MR. BLASIER:

Now, it is a little difficult to see on the big screen, but could you direct the arrow to the part that you cut out yourself?

369 MR. MARTZ:

Down, a little bit more. Right there, (Indicating). Right there, (Indicating).

370 MR. BLASIER:

Now, that is what you called Q206, correct?

371 MR. MARTZ:

That's correct.

372 MR. BLASIER:

And the hole there is where Q207 came from; is that right?

373 MR. MARTZ:

Yes.

374 MR. BLASIER:

Did you examine--did you examine the sock to determine the outer edge of the bloodstain that had been in that area?

375 MR. MARTZ:

Yes.

376 MR. BLASIER:

And did your cutting there go past the outer edge?

377 MR. MARTZ:

Not to my knowledge.

378 MR. BLASIER:

So it is your understanding or your recollection that the bloodstain came out further than the edge of your cutting?

379 MR. MARTZ:

Yes.

380 (Discussion held off the record between Defense counsel.)
381 MR. BLASIER:

Could we go back to 1257-P.

382 (Discussion held off the record between Defense counsel.)
383 MR. BLASIER:

1257-P again.

384 MR. BLASIER:

Now, this is what you were just describing as the cut-out on the sock that you made?

385 MR. MARTZ:

Yes.

386 MR. BLASIER:

Except turned upside down?

387 MR. MARTZ:

Right.

388 MR. BLASIER:

Now, did you do any testing at all to determine whether there was more blood in Q207 or less blood than there was in Q206?

389 MR. MARTZ:

No.

390 (Discussion held off the record between Defense counsel.)
391 MR. BLASIER:

Is it accurate, Agent Martz, that--let's assume hypothetically that Q207 had more blood in it than Q206. Do you have that in mind?

392 (No audible response.)
393 MR. BLASIER:

Would you agree that if that stain had been made with EDTA blood that you would likely find more of it in Q207 than Q206 if Q207 had more blood in it?

394 MS. CLARK:

Objection. Improper hypothetical and assuming facts not in evidence.

395 THE COURT:

Sustained.

396 MR. BLASIER:

Well, when you are trying to detect EDTA, would you agree that the amount you are likely to detect, if it is there, is going to be dependent on how much you start with in your testing?

397 MR. MARTZ:

Yes.

398 MR. BLASIER:

And if you start with less blood that has EDTA in it, would you agree that you are likely to find or have a lower likelihood of finding EDTA than if you had a larger quantity of blood with EDTA in it?

399 MR. MARTZ:

Well, certainly it would depend on the size we are talking about. If we are talking very small differences, you may or may not, but if we are talking large differences, then you will find differences.

400 (Discussion held off the record between Defense counsel.)
401 MR. BLASIER:

Did you do any testing whatsoever to determine whether the amounts of blood in the sock--let me rephrase. Did you do any testing to determine whether the concentration of blood in that large stain varied from the outer edge to the center?

402 MS. CLARK:

Objection. Impossible.

403 THE COURT:

Overruled.

404 MR. MARTZ:

Well, I didn't even have the center, so it would have been a difficult test to determine.

405 MR. BLASIER:

Well, you had Q207, didn't you?

406 MR. MARTZ:

Right, but that still isn't the center.

407 MR. BLASIER:

If you wanted to you could have extracted the blood from Q207 and compared it to Q206, couldn't you?

408 MR. MARTZ:

I saw no reason to, but I certainly could have done it.

409 (Discussion held off the record between Defense counsel.)
410 MR. BLASIER:

Well, is the reason that you didn't do that is because you didn't know what Q207 was?

411 MR. MARTZ:

207, I didn't know exactly what it was. That is why the first day I combined 207 and 206 and treated them as the same, because I didn't know the origin of 207.

412 MR. BLASIER:

Now, Agent Martz, do you agree that in order for EDTA to be detected in your method, it must be water soluble?

413 MR. MARTZ:

Yes.

414 MR. BLASIER:

In other words, a compound that might have the same molecular weight and the same daughter ions as EDTA, if it wasn't water soluble, you wouldn't be able to measure it under your system?

415 MR. MARTZ:

Well, it depends, too. I mean, when you are talking about parts per million, parts per billion, in literature a lot of time they will report things as not soluble in water and yet in reality you can identify things and trace quantity. It would depend on the individual chemical.

416 MR. BLASIER:

But it would have to be water soluble, wouldn't it?

417 MR. MARTZ:

Well, not necessarily. I mean, when you are talking parts per billion or million, and you are talking about a complex mixture, we put in solution things that literature says that are insoluble in water and identified them. I mean--

418 MR. BLASIER:

There are a lot of things that aren't soluble in water, too?

419 MR. MARTZ:

When they say soluble, in referring--they are not referring to parts per million, parts per billion.

420 MR. BLASIER:

There are a lot of things?

421 MR. MARTZ:

There are a lot of things that are not listed as not soluble in water that will dissolve in water.

422 MR. BLASIER:

Would you agree that for a compound to have the characteristics of EDTA that you found it would also have to be heat stable?

423 MR. MARTZ:

I don't know--it depends on your definition of heat stable. It is--

424 MR. BLASIER:

Do you know what that term means?

425 MR. MARTZ:

Well, yeah, but what heat? Are we talking about? Are we talking about a hundred degrees, 500 degrees, a thousand degrees? I don't understand--I mean, that is a broad term.

426 MR. BLASIER:

Must the chemical that you are looking at, in order it to--to go through your system, be soluble in the specific mobile phase, that is, the liquid that you use to send it through the column?

427 MR. MARTZ:

It certainly helps.

428 MR. BLASIER:

Okay. Now, have you run tests on any other compound, other than EDTA, that gives you the results you got in this case for the gate and the sock; namely, the retention time that you got, the presence of the parent ion, the presence of the daughter ion?

429 MR. MARTZ:

Umm, I ran in other chemicals with this testing.

430 MR. BLASIER:

Have you ever tested, in the course of your 17 year's experience with mass spectrometry, any chemical that has those characteristics other than EDTA?

431 MR. MARTZ:

I don't know right offhand.

KEY QUOTE
432 MR. BLASIER:

Do you know of any that you have run that have those characteristics?

433 MR. MARTZ:

Umm, I don't think that I have.

434 MR. BLASIER:

Now, you have in the--I think yesterday been attempting to find some compound that might look like this?

435 MR. MARTZ:

Well, I have been attempting to find--locate other chemicals that could possibly give similar results, yes.

436 MR. BLASIER:

Okay. And you handed me a picture of a chemical this morning?

437 MR. MARTZ:

That's correct.

438 MR. BLASIER:

Now, let me have this marked next.

439 THE COURT:

1267--1266.

440 MR. BLASIER:

1266?

441 THE COURT:

Yes.

442 (Deft's 1266 for id = chart)
443 MR. BLASIER:

Let me show you 1266. Is that a chart that you handed me this morning?

444 MR. MARTZ:

Yes, it is.

445 MR. BLASIER:

And what is that for?

446 MR. MARTZ:

It is a mass spectrum of a chemical.

447 MR. BLASIER:

What is it called?

448 MR. MARTZ:

Benfluralin.

449 MR. BLASIER:

Do you have any idea what it is?

450 MR. MARTZ:

I believe it is an environmental contaminant.

451 MR. BLASIER:

Do you know?

452 MR. MARTZ:

That is what I was told on the phone this morning. I don't have any other knowledge other than that.

453 MR. BLASIER:

Do you know where it is found?

454 MR. MARTZ:

Evidently in the environment.

455 MR. BLASIER:

Do you know where in the environment?

456 THE COURT:

How about if you spell it for the--

457 MR. MARTZ:

B-E-N-F-L-U-R-A-L-I-N.

458 MR. BLASIER:

Do you know where in the environment?

459 MR. MARTZ:

No.

460 MR. BLASIER:

And what is the parent ion for that compound?

461 MR. MARTZ:

335.

462 MR. BLASIER:

Now, you haven't tested that compound to see if it looks like EDTA, have you?

463 MR. MARTZ:

Today is the first time I have seen this chemical.

464 MR. BLASIER:

Okay. And the mass spec that was generated there was done with a different method from your electrospray; is that correct?

465 MR. MARTZ:

That's correct.

466 MR. BLASIER:

What method was used?

467 MR. MARTZ:

This is the standard electron impact ionization.

468 MR. BLASIER:

Do you have any way of knowing, without estimating whether if you have run the same tests on that, whatever it is, that you would get the same pattern as EDTA?

469 MR. MARTZ:

I have no way of knowing other than testing. The purpose for this chemical is it had some properties similar to EDTA in its mass spectrum, but the only way to prove whether or not it would give the same result or not would be to actually analyze the chemical.

470 MR. BLASIER:

Once you got the results that you got in this case in February did you make any effort to find some compound other than EDTA that would account for what you found on the back gate and the socks?

471 MR. MARTZ:

No.

472 THE COURT:

10:30.

473 (Brief pause.)
474 MR. BLASIER:

Do you recall the testimony yesterday about the EPA documents that were presented by Miss Clark to Dr. Rieders?

475 MR. MARTZ:

Yes, that's correct.

476 (Brief pause.)
477 MR. BLASIER:

Let me show you 12--I'm sorry, People's 537. Is that the reference that you are thinking of?

478 MR. MARTZ:

Yes, that's correct.

479 MR. BLASIER:

Now, that is not an article, is it?

480 MR. MARTZ:

No.

481 MR. BLASIER:

It is a description of what--of an article?

482 MR. MARTZ:

Yes, that's correct.

483 MR. BLASIER:

And where did that article appear?

484 MR. MARTZ:

In the Brit Veterinarian Journal, I believe.

485 MR. BLASIER:

I'm sorry, which?

486 MR. MARTZ:

The--

487 MR. BLASIER:

Do you know which journal?

488 MR. MARTZ:

It is Brit, so I don't know if it is the British or the Britain, but "Vet" is evidently veterinarian and "J" is obviously journal.

489 MR. BLASIER:

Did you recall yesterday Miss Clark asking Dr. Rieders questions about that document as it relates to the maximum daily allowance of EDTA?

490 MR. MARTZ:

I don't know if it necessarily had to do with maximum daily allowance or what you would expect to find in a person. I think it was more relating to how much you would expect to find in a person's blood.

491 MR. BLASIER:

Does that abstract indicate that you would expect to find 2000 parts per million in anybody's blood?

492 MR. MARTZ:

No.

493 MR. BLASIER:

And umm--

494 MR. MARTZ:

It states that it should not exceed 2000 parts per million.

495 MR. BLASIER:

What is the concentration of EDTA in a purple-topped tube?

496 MR. MARTZ:

Somewhere between a thousand and 2000 parts per million.

497 MR. BLASIER:

Would you agree that if someone had 2000 parts per million EDTA in their blood they would be dead?

498 MR. MARTZ:

Well, for any sustained period of time. I think they use it also for transfusions. I don't know the exact amount that they use. It would not be a good idea, I don't think, to have that amount in your blood, I agree with that.

499 MR. BLASIER:

Does that number bear any relationship at all to what the FDA allows in terms of EDTA as a food additive?

500 MR. MARTZ:

Umm, no. No, I don't believe it does.

501 MR. BLASIER:

And it is your understanding that particular study was a study on fish?

502 MR. MARTZ:

Umm, that's correct.

503 MR. BLASIER:

And it was to determine the toxic level that would kill fish?

504 MR. MARTZ:

No. I did some further research and actually the whole reference has to do with how much EDTA is used to preserve food. It has absolutely nothing to do whatsoever with how much you would expect to find in fish or humans. It was completely out of context.

505 MR. BLASIER:

Okay. Now, I want to ask you about EDTA that you might expect in your blood from food. And you have provided us several articles that you found related to that topic, have you not?

506 MR. MARTZ:

Right.

507 MR. BLASIER:

Let me show you an article--can we have this marked, I'm sorry, 1260--

508 THE CLERK:

7.

509 MR. BLASIER:

1267.

510 THE CLERK:

Yes.

511 MR. BLASIER:

Okay.

512 (Deft's 1267 for id = article)
513 MR. BLASIER:

Let me show you 1267. Do you recall Miss Clark yesterday mentioning the figure of 50 milligrams per day as a possible amount of EDTA that someone might take into their system?

514 MR. MARTZ:

Yes, that's correct.

515 MR. BLASIER:

And is that the article that that came from?

516 MR. MARTZ:

Yes.

517 MR. BLASIER:

Why don't you just give us the name of that article.

518 MR. MARTZ:

It is the "Food iron absorption in man. The effect of EDTA on absorption of dietary non-heme iron."

519 MR. BLASIER:

Now, you also were shown yesterday some excerpts from the code of federal regulations. Do you recall that?

520 MR. MARTZ:

Yes.

521 MR. BLASIER:

Could we--I don't have the exhibit number on this one, your Honor.

522 MR. BLASIER:

I found it.

523 (Brief pause.)
524 MR. BLASIER:

I show you People's 539. Take a look at that again. Is that the document that describes what the FDA says is the allowable maximum amounts of EDTA in food preservatives or food substances?

525 MR. MARTZ:

That's correct.

526 MR. BLASIER:

And I would like to put that on the elmo again. Now, this is a document that you provided to us as well, is it not?

527 MR. MARTZ:

That's correct.

528 MR. BLASIER:

Now, it is your understanding that the 50 milligram per day figure that is in that article that you provided to us was based on what the FDA says are the maximum levels of EDTA you can put in food?

529 MR. MARTZ:

I would say that had most of the basis for it, yes.

530 MR. BLASIER:

Now, could we move that up just a little bit, Mr. Harris.

531 MR. BLASIER:

Now, this regulation talks about parts per million, 220 parts per million, 33 parts per million. That bears no relationship to parts per million in food, does it?

532 MR. MARTZ:

No.

533 MR. BLASIER:

That is what you can put in the food?

534 MR. MARTZ:

Yes.

535 MR. BLASIER:

That then gets eaten and greatly diluted?

536 MR. MARTZ:

Right, yes, yes.

537 MR. BLASIER:

Now, you also provided us a study from 1954 concerning the metabolism of EDTA in humans, correct?

538 MR. MARTZ:

Umm, I don't think it primarily dealt with metabolism. It was an article about EDTA being injected in humans. I think--

539 MR. BLASIER:

Okay.

540 MR. MARTZ:

--I think they did mention it was not metabolized, but I don't think that was the purpose of the article.

541 MR. BLASIER:

Right. This was an article that you provided to us?

542 MR. MARTZ:

Right, yes.

543 MR. BLASIER:

And an article that you relied upon in forming your opinions in this case?

544 MR. MARTZ:

No, I don't believe so.

545 MR. BLASIER:

Okay. Now, it is an article that you reviewed and we have discussed, haven't we?

546 MR. MARTZ:

It is an article reviewed. I reviewed many articles on EDTA. That was one of them.

547 MR. BLASIER:

Now, what is your understanding as to the body of literature on EDTA, such as it is, in terms of how much EDTA that you eat in food actually gets into your blood?

548 MR. MARTZ:

Umm, it is unclear. The best is that paper there from 1954, but even in that paper it mentions some data which is conflicting and there hasn't been a whole lot of data since then. Most of the other papers even today refer back to that paper in 1954. I believe it is not well-known.

549 MR. BLASIER:

What does this paper say?

550 MR. MARTZ:

In that one, the absorption?

551 MR. BLASIER:

Yes.

552 MR. MARTZ:

It says five percent is absorbed.

553 MR. BLASIER:

There is other literature that says that as well; is that correct?

554 MR. MARTZ:

I think all the other literature is based on that, to my knowledge. There is no other independent study that I could find.

555 MR. BLASIER:

Well, what is--you provided us some other literature that says the same thing, didn't you?

556 MR. MARTZ:

Yes, yes. I mean, it was mentioned in a lot of articles that that was the absorption, I agree with that.

557 MR. BLASIER:

Did you provide us with some excerpts from a textbook called "The pharmacological basis of therapeutics by Goodman and Gilmans?

558 MR. MARTZ:

Yes.

559 MR. BLASIER:

Is that an accepted text in the field of pharmacology?

560 MR. MARTZ:

Yes.

561 MR. BLASIER:

What does that indicate in terms of the absorption of EDTA that you take in by mouth into the blood?

562 MR. MARTZ:

I assume it says five percent.

563 MR. BLASIER:

Okay. Now, would you like to look at that to confirm it?

564 MR. MARTZ:

No I'm sure it says five percent.

565 MR. BLASIER:

Now, when we talk about absorption into the blood, when you eat something, it doesn't just go into the blood, does it?

566 MR. MARTZ:

No, no.

567 MR. BLASIER:

What happens to it in the stomach in terms of how it gets to the blood versus how it gets excreted in other ways?

568 MR. MARTZ:

Well, we are trailing a little bit out of my field, but certainly in order to survive things have to be absorbed into the blood stream. If you eat everything and nothing gets absorbed, you are going to die.

569 MR. BLASIER:

Now, the studies indicate, the `54 study indicates that the vast majority, ninety percent or more of the EDTA that you might eat gets excreted through the feces and never gets to the blood, correct?

570 MR. MARTZ:

That is what that one paper showed, yes.

571 MR. BLASIER:

When we talk about a five percent absorption rate, we are talking about of the, let's say, of the 50 milligrams that a person might eat in a day, only five percent of that actually gets into the blood at some point?

572 MR. MARTZ:

Yeah. Approximately two and a half milligrams, according to that paper.

573 MR. BLASIER:

Now, that paper also talks about when it gets into the blood stream that it also gets into other extracellular fluid, in other words, other fluid in the body, correct?

574 MR. MARTZ:

Right, correct.

575 MR. BLASIER:

And the total volume approximately of this other fluid in the body is what?

576 MR. MARTZ:

I think the paper there may have used forty liters. It would depend of course on the size of the individual, so that would be probably an average.

577 MR. BLASIER:

Now, would you agree that it is a relatively easy calculation to figure out if you had 2.5 milligrams in forty liters how much parts per million, billion or whatever that is?

578 MR. MARTZ:

Right, yeah.

579 MR. BLASIER:

What is that figure?

580 MR. MARTZ:

I believe it was sixty parts per billion, approximately. Approximately sixty parts per billion.

581 MR. BLASIER:

We are talking in the range of parts per billion rather than parts per million, correct?

582 MR. MARTZ:

According to this study, yes.

583 MR. BLASIER:

Now, under that set of conditions that I just described to you, that assumes, does it not, that whatever gets absorbed into the blood is all there at the time that you take the measurement?

584 MR. MARTZ:

That's correct.

585 MR. BLASIER:

Correct?

586 MR. MARTZ:

Yes.

587 MR. BLASIER:

Now, what does the literature indicate in terms of how quickly EDTA that does get into the blood stream gets out of the blood stream?

588 MR. MARTZ:

Well, its half-life is very short. It leaves the blood stream very quickly, according to that paper.

589 MR. BLASIER:

Are we talking in terms of minutes or hours?

590 MR. MARTZ:

I think it is hours.

591 MR. BLASIER:

Would you like to look at that article to refresh your memory?

592 (Brief pause.)
593 MR. MARTZ:

Its half-life would be an hour.

594 MR. BLASIER:

And by "Half-life" does that mean that once this, let's say, sixty parts per billion gets into your system, one hour later there is only going to be half as much?

595 MR. MARTZ:

That's correct.

596 MR. BLASIER:

And one hour after that there is going to be half again as much?

597 MR. MARTZ:

Yes.

598 MR. BLASIER:

So that it is quickly very quickly eliminated from the system?

599 MR. MARTZ:

That's correct. That is according to that paper in 1954.

600 MR. BLASIER:

Now, would you agree that under those circumstances that we have described that is consistent with the literature, that the amount of EDTA that you might expect to find in a person's blood after they ate something with EDTA in it is likely to be very, very small, in the range of parts per billion?

601 MR. MARTZ:

Well, I think if you take everything into account it would be difficult to say that. I mean, you are looking at one study in 1954 and it mentions at the end of that that there its some conflicting data based on iron and yttrium being eliminated very quickly from the body when it is ingested, when EDTA is ingested, and that paper only mentions one of the salts that the FDA permits to be used in the food. There is two other salts. So relying totally on one paper in 1954 with a lot of other conflicting information and information that is not available, I--to be perfectly honest with you, I don't believe that anyone knows exactly how much EDTA is present.

602 MR. BLASIER:

Well, when you say a lot of conflicting information, what conflicting information are you talking about?

603 MR. MARTZ:

Well, conflicting information with iron studies, the fact that it indicates that more is absorbed than the five percent.

604 MR. BLASIER:

What paper says that?

605 MR. MARTZ:

This particular paper here, the last paragraph.

606 MR. BLASIER:

Do you have that in front of you?

607 MR. MARTZ:

Second to last paragraph.

608 MR. BLASIER:

Do you have that in front of you?

609 MR. MARTZ:

No. You took it back from me, I think.

610 MR. BLASIER:

I think I did.

611 (Brief pause.)
612 MR. BLASIER:

Is that what you are referring to, (Indicating)?

613 MR. MARTZ:

Right, yes, exactly. Would you like me to read it?

614 MR. BLASIER:

Let me put it on the elmo and then you can read it.

615 MR. MARTZ:

Okay.

616 (Brief pause.)
617 MR. BLASIER:

Perhaps we should mark this.

618 THE COURT:

1268.

619 MR. BLASIER:

1268.

620 THE COURT:

1268 and we will wind it up with this one.

621 MR. BLASIER:

I'm sorry.

622 THE COURT:

Wind it up.

623 (Deft's 1268 for id = article)
624 MR. BLASIER:

Now, the paragraph you are referring to is the one that has the little asterisk in front of it; is that correct?

625 MR. MARTZ:

That's correct.

626 MR. BLASIER:

Why don't you read this.

627 MR. MARTZ:

"The low absorption after oral administration is very surprising in view of the findings that material"--

628 MS. CLARK:

Objection, your Honor. Could we ask Mr. Martz to speak into the microphone. I can't hear.

629 THE COURT:

All right.

630 MR. MARTZ:

"The low absorption after oral administration is very surprising in view of the finding that the material is effective by that route in accelerating the excretion of yttrium and lead. There is no satisfactorily readily apparent explanation at the present time" or "At this present time."

631 MR. BLASIER:

Now, would you agree that what that says is that EDTA is able to help remove yttrium and lead from the blood very quickly?

632 MR. MARTZ:

Yes, well, yes.

633 MR. BLASIER:

That is another indication?

634 MS. CLARK:

Objection. It does not say "Very quickly." Misstates the evidence.

635 THE COURT:

Overruled.

636 MR. BLASIER:

Is that a fair characterization, what I just said?

637 MR. MARTZ:

Well, I don't agree with you a hundred percent on that.

638 MR. BLASIER:

Okay. But there is no data there, is there?

639 MR. MARTZ:

No.

640 MR. BLASIER:

And that doesn't say that EDTA is absorbed more than five percent in blood, does it?

641 MR. MARTZ:

Well, it kind of implies that to me.

642 MR. BLASIER:

It doesn't say that, does it?

643 MR. MARTZ:

It doesn't say that.

644 MR. BLASIER:

What it says is it is very effective of getting things out of the blood quickly?

645 MS. CLARK:

Objection.

646 MR. MARTZ:

The only way to get it out of the blood is to get it into the blood first of all.

647 MR. BLASIER:

And then get it out quickly?

648 MR. MARTZ:

It is a chelating blood. Once it goes in the blood it chelates and gets in the body and will be excreted.

649 MR. BLASIER:

Okay.

650 THE COURT:

Ladies and gentlemen, we are going to take our mid-morning recess at this time. Remember all my admonitions to you. We will be in recess for fifteen minutes. And Agent Martz, you can step down and we will be back in fifteen minutes.

Temperature

tense

Key Quotes (5)

Roger Martz
We would like you to test these items for the presence/absence of EDTA in order to refute the possibility that the stains on the sock, item 13, could have come from Nicole's reference sample, 59 or 72.
Martz reads aloud the prosecution's own letter, which explicitly frames the testing as an effort to 'refute' a specific conclusion — suggesting the lab was asked to produce a particular result rather than conduct neutral science.
Roger Martz
Yes... it certainly warrants further testing. It responded like EDTA responded, yes... Yes.
After persistent questioning, Martz concedes that the sock blood results are consistent with the presence of EDTA — the core of the defense's planted-blood theory.
Roger Martz
I don't know right offhand... I don't think that I have.
Martz cannot identify any other compound besides EDTA that would produce the same retention time, parent ion, and daughter ion pattern he observed — undercutting his own suggestion that the results might have another explanation.
Roger Martz
No. I was trying to determine whether or not the stain came from EDTA-preserved blood... My method was designed to determine whether or not it was preserved blood with EDTA.
Martz repeatedly resists Blasier's framing that his test was binary (present/absent) — but never explains why he then chose the least sensitive confirmation method available.
Lance A. Ito
Agent, the world's best is 2:06.
Judge Ito corrects Martz mid-analogy when he claims elite marathon runners finish in two hours — a rare moment of judicial levity in an otherwise dense technical proceeding.

Evidence (15)

Defense 1263
February 16, 1995 letter from prosecution to FBI requesting EDTA testing, with language asking to 'refute the possibility' of planted blood
read aloud by Martz; central to bias argument
Defense 1264
Photograph of Q207, the sock center stain swatch sent to FBI
introduced and displayed on Elmo
Defense 1265
Photograph of the sock taken by Martz upon receipt at FBI lab
introduced; used to show location of Q206 cut and Q207 hole
Defense 1262-A/B
Chromatograms of 50 parts per million EDTA standards run February 22
used to demonstrate instrument variation in ion count
Defense 1259-A/B/C
Chromatograms and daughter ion spectra for Q206 (sock edge cutting)
discussed; Martz confirms peaks consistent with EDTA parent and daughter ions
Defense 1260-A/B
Analysis runs for Q204 (back gate bloodstain)
discussed; Martz confirms results consistent with EDTA
+ 9 more

Notable Exchanges (4)

Robert BlasierRoger Martz
Blasier systematically walks Martz through three confirmation methods — full daughter scan (130-295 range), narrow scan (130-134), and selected reaction monitoring (just 160) — and gets Martz to confirm that the full daughter scan is the 'least' sensitive for detecting the 132 ion, then asks why he chose that method. Martz defends it as necessary for positive identification, but cannot fully reconcile choosing the least sensitive detection method when trying to confirm presence.
strategic
Robert BlasierRoger Martz
Blasier confronts Martz with the prosecution's letter language asking the FBI to 'refute the possibility' that evidence blood came from preserved reference samples. Martz insists he did not infer a desired result from that phrasing, but the letter wording is now in the record.
revealing
Robert BlasierRoger Martz
Blasier reveals that Martz handed him a chart for Benfluralin — an alleged EDTA analog — the morning of testimony, and that Martz learned of it only by phone that morning and has never tested it. This undercuts the prosecution's suggestion that something other than EDTA could explain the results.
revealing
Robert BlasierRoger Martz
Extended colloquy on dietary EDTA absorption: Blasier walks Martz through the math — 50mg consumed, 5% absorbed, distributed across 40 liters of body fluid, half-life of one hour — arriving at ~60 parts per billion in blood that rapidly clears. This establishes that background EDTA from food cannot explain the levels Martz found.
strategic

Light Moments (1)

Lance A. Ito
Martz uses a marathon analogy to explain his chromatography's poor separation — saying all compounds finish at the same time like a 50-yard dash. Judge Ito immediately corrects the embedded premise: 'Agent, the world's best is 2:06.'

Credibility Attacks (4)

⚔ Roger Martz
inexperience / lack of qualification
Blasier establishes that Martz had never analyzed for EDTA before this case, had never designed a method to extract EDTA from dried bloodstains, and developed his protocol in roughly one week — undermining his authority as the expert who cleared the prosecution's evidence.
⚔ Roger Martz
methodological inadequacy
Blasier shows that Martz used a chromatography method he describes with a '50-yard dash' analogy — poor at separating compounds — when better alternatives existed (gradient elution, gas chromatography with derivatization), and that he chose the least sensitive of three available methods to confirm the critical 132 daughter ion.
⚔ Roger Martz
bias / outcome-oriented testing
Blasier gets Martz to read aloud the prosecution's letter asking him to 'refute the possibility' that evidence blood came from preserved reference samples, framing the entire EDTA investigation as designed to produce a predetermined exculpatory result for the prosecution.
⚔ Roger Martz
incomplete testing / selective analysis
Martz admits he did not test Q207 (the larger sock stain) in the more sensitive positive ion mode because he did not know what it was, and never requested it back after learning its origin. He also never used selected reaction monitoring or a narrow scan to confirm the 132 daughter ion in either the sock or gate samples.

Witness Demeanor

(No audible response) — Martz goes silent when Blasier asks whether he agrees that a compound with similar mass characteristics to EDTA would need to be water soluble
(No audible response) — Martz goes silent when asked whether he agrees that more blood with EDTA would yield more detectable EDTA

Objections

5 objections (1 sustained, 3 overruled)
Proceeding 7021 • 650 utterances • Defense witness
Criminal Trial
Department 103
⚖️ Start
📂 JUL 25, 1995 📄 Direct examination of Roger Ma
JUL 25, 1995 KRT DvH TD